Radar on Specialty Pharmacy

Study Finds Wide Variation in Payers’ CAR-T Drug Costs

Chimeric antigen receptor T cell (CAR-T) therapies have been available in the U.S. since August 2017. While the list prices for the one-time treatments are known, a recent study from Prime Therapeutics LLC examined ...
0 Comments
© 2024 MMIT

Report: Specialty Drug Spending May Be Slowed by Biosimilars

Based on invoice price levels, the IQVIA Institute for Human Data Science anticipates that the global medicine market will experience a 3% to 6% compound annual growth rate (CAGR) through 2025. Oncology and immunolo...
0 Comments
© 2024 MMIT

Study Finds Good Adherence, Low ADE Rates With Oral DMTs

The multiple sclerosis (MS) therapeutic class boasts more than 20 disease modifying therapies (DMTs) that have various routes of administration. A recent study of oral therapies to treat relapsing-remitting MS (RRMS...
0 Comments
© 2024 MMIT

Integrated Medical, Pharmacy Claims Give Full View of AI Class

Some companies that analyze specialty drug spend do so with a focus solely on the pharmacy benefit. This approach, however, may fail to take into account a significant amount of medical benefit spending within certa...
0 Comments
© 2024 MMIT

New FDA Specialty Approvals

✦ April 6: The FDA approved a new dosing regimen for Eli Lilly and Co.’s Erbitux (cetuximab) of 500 mg/m2 as a 120-minute infusion every two weeks as a single agent or in combination with chemotherapy for people...
0 Comments
© 2024 MMIT

News Briefs

The FDA’s Oncologic Drugs Advisory Committee voted to keep most indications for a handful of immune checkpoint inhibitors that target programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and received accelera...
0 Comments
© 2024 MMIT

Evaluation of Certain Cancer Drugs Illustrates Risk/Reward Balance

The FDA is conducting an industrywide evaluation of drugs with indications given accelerated approval in an effort to determine whether confirmatory clinical trials verified the therapies’ clinical benefits. Manuf...
0 Comments
© 2024 MMIT

Collaboration Is Needed on COVID Vaccine Dosing, Specialty Drugs

Many people taking specialty medications, such as people with cancer, are immunocompromised, and specialty drugs themselves can cause drug-induced immunosuppression. As COVID-19 vaccines roll out, it may be unclear ...
0 Comments
© 2024 MMIT

Oncologists Say They Expect To Prescribe Fotivda for RCC

The renal cell carcinoma (RCC) therapeutic class boasts multiple agents, but a recent entrant is offering a new tool for certain patients. A Zitter Insights survey shows that the majority of oncologist respondents a...
0 Comments
© 2024 MMIT

DMT Adherence While Pregnant Is Tied to Lower Medical Costs

Women diagnosed with multiple sclerosis (MS) and being treated with disease-modifying therapies (DMTs) who become pregnant often discontinue those agents, as none are approved for use during pregnancy. But a recent ...
0 Comments
© 2024 MMIT